文献速递糖尿病

低浓度IL-1β通过增加人源化小鼠胰岛体外释放hIAPP促进胰岛淀粉样蛋白形成

Low concentration IL-1β promotes islet amyloid formation by increasing hIAPP release from humanised mouse islets in vitro.
PubMed 文献 · Diabetologia · 2020-07-29

研究使用内源性β细胞表达hIAPP的人源化小鼠模型,在体外观察低浓度(4 pg/ml)IL-1β对胰岛淀粉样蛋白形成的影响。结果显示IL-1β处理48小时增加含淀粉样蛋白胰岛比例和淀粉样蛋白面积,并增加IAPP和胰岛素释放,该效应可被IL-1β中和抗体阻断;无细胞聚集实验未显示IL-1β直接影响hIAPP聚集。作者认为生理相关水平IL-1β通过增加β细胞释放IAPP促进胰岛淀粉样蛋白形成。

要点

  • 低浓度IL-1β(4 pg/ml)处理48小时增加hIAPP表达小鼠胰岛的淀粉样蛋白形成。
  • IL-1β增加胰岛IAPP和胰岛素释放,该效应可被IL-1β中和抗体阻断。
  • 无细胞实验显示IL-1β不直接影响hIAPP聚集动力学。

核心结论

  • 在淀粉样蛋白形成条件下,生理相关水平的IL-1β通过增加β细胞释放IAPP促进胰岛淀粉样蛋白形成。
  • 中和IL-1β的这一效应可能减轻胰岛淀粉样蛋白形成对β细胞功能和存活的有害影响。

研究设计与样本

  • 使用内源性β细胞表达hIAPP的人源化小鼠模型,在体外将形成淀粉样蛋白的胰岛培养48小时,分别在有或无IL-1β、有或无IL-1β中和抗体的条件下处理。
  • 通过免疫组化评估胰岛形态,定量胰岛mRNA表达、激素含量和释放,并用无细胞硫磺素T实验监测hIAPP聚集动力学。

主要发现

  • 低浓度IL-1β(4 pg/ml)处理48小时增加含淀粉样蛋白胰岛比例(93.52 ± 3.89% vs 43.83 ± 9.67%)和淀粉样蛋白严重程度(淀粉样蛋白面积/胰岛面积 4.45 ± 0.82% vs 2.16 ± 0.50%)。
  • IL-1β处理组48小时内IAPP释放为0.409 ± 0.082 pmol/5胰岛 vs 对照组0.165 ± 0.051 pmol/5胰岛;胰岛素释放为87.5 ± 8.81 pmol/5胰岛 vs 对照组48.3 ± 17.3 pmol/5胰岛,该效应可被IL-1β中和抗体共处理阻断。
  • 无细胞hIAPP聚集实验显示IL-1β对hIAPP体外聚集无影响。
  • 低浓度IL-1β未增加未折叠蛋白反应标志物(Atf4、Ddit3)或改变促IAPP加工酶基因表达(Pcsk1、Pcsk2、Cpe)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Aggregation of the beta cell secretory product human islet amyloid polypeptide (hIAPP) results in islet amyloid deposition, a pathological feature of type 2 diabetes. Amyloid formation is associated with increased levels of islet IL-1β as well as beta cell dysfunction and death, but the mechanisms that promote amyloid deposition in situ remain unclear. We hypothesised that physiologically relevant concentrations of IL-1β stimulate beta cell islet amyloid polypeptide (IAPP) release and promote amyloid formation. METHODS: We used a humanised mouse model of endogenous beta cell hIAPP expression to examine whether low (pg/ml) concentrations of IL-1β promote islet amyloid formation in vitro. Amyloid-forming islets were cultured for 48 h in the presence or absence of IL-1β with or without an IL-1β neutralising antibody. Islet morphology was assessed by immunohistochemistry and islet mRNA expression, hormone content and release were also quantified. Cell-free thioflavin T assays were used to monitor hIAPP aggregation kinetics in the presence and absence of IL-1β. RESULTS: Treatment with a low concentration of IL-1β (4 pg/ml) for 48 h increased islet amyloid prevalence (93.52 ± 3.89% vs 43.83 ± 9.67% amyloid-containing islets) and amyloid severity (4.45 ± 0.82% vs 2.16 ± 0.50% amyloid area/islet area) in hIAPP-expressing mouse islets in vitro. This effect of IL-1β was reduced when hIAPP-expressing islets were co-treated with an IL-1β neutralising antibody. Cell-free hIAPP aggregation assays showed no effect of IL-1β on hIAPP aggregation in vitro. Low concentration IL-1β did not increase markers of the unfolded protein response (Atf4, Ddit3) or alter proIAPP processing enzyme gene expression (Pcsk1, Pcsk2, Cpe) in hIAPP-expressing islets. However, release of IAPP and insulin were increased over 48 h in IL-1β-treated vs control islets (IAPP 0.409 ± 0.082 vs 0.165 ± 0.051 pmol/5 islets; insulin 87.5 ± 8.81 vs 48.3 ± 17.3 pmol/5 islets), and this effect was blocked by co-treatment with IL-1β neutralising antibody. CONCLUSIONS/INTERPRETATION: Under amyloidogenic conditions, physiologically relevant levels of IL-1β promote islet amyloid formation by increasing beta cell release of IAPP. Neutralisation of this effect of IL-1β may decrease the deleterious effects of islet amyloid formation on beta cell function and survival.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Templin AT, Mellati M, Meier DT, et al. Low concentration IL-1β promotes islet amyloid formation by increasing hIAPP release from humanised mouse islets in vitro. Diabetologia. 2020. PMID: 32728889. doi:10.1007/s00125-020-05232-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。